| EN
For the years of 2017, 2018 ,2019 and 2020 Simcere's research and development costs accounted for 5.5%, 9.9% ,14.2% and 25.3%, respectively, of its total revenue for the total periods. We have established three R&D centers including one in Nanjing, Jiangsu, one in Shanghai and one in Boston, the United States. With the approval of the Ministry of Science and Technology, we also established a national key laboratory of translational medicine and innovative pharmaceuticals.

Global R&D Center Layout

Boston R&D Center

Nanjing R&D Center

Shanghai R&D Center

R&D Pipeline

We have nearly 60 innovative product candidates in different stages of development, among which over 10 product candidates had obtained the IND approval or were at clinical stage.

MORE+
Simcere was approved by the Ministry of Science and Technology of the PRC in October 2015 to establish the only state key laboratory of translational medicine and innovative pharmaceuticals in the PRC pharmaceutical industry. Since its establishment, we have made rapid progress in critical technologies breakthroughs, new drug development, talent training and team building.
This laboratory focuses on the translational medicine and precision medicine-based research and development of innovative pharmaceuticals for the treatment of oncology, central nervous system diseases, autoimmune diseases and infectious diseases.
The laboratory’s several goals include establishing key translational medicine technologies for new drug development, creating an integrated platform for general translational medicine technology research, and providing exemplary models of platform setup (including required key technologies) and industry standards for new drug development within translational medicine.

Massachusetts is home to 19% of the top pharmaceutical product pipelines in the United States and 9% globally. The state capital, Boston, in particular holds a dominating position in the global life sciences community.

Simcere’s Boston R&D Center focuses on the world's cutting-edge cell and gene therapies, and with its team of pioneering scientists, it remains dedicated to building a world-class R&D center. Utilizing the world's state-of-the-art technologies, we are rapidly building several cutting-edge technology platforms for cell and gene therapies and thereby making the Boston R&D Center a powerful pipeline driver for Simcere through the institute’s fast and efficient project promotion system.